320 related articles for article (PubMed ID: 2479719)
1. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease.
Taylor KM; Jagannath S; Spitzer G; Spinolo JA; Tucker SL; Fogel B; Cabanillas FF; Hagemeister FB; Souza LM
J Clin Oncol; 1989 Dec; 7(12):1791-9. PubMed ID: 2479719
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte colony-stimulating factor stimulates recovery of granulocytes in patients receiving dose-intensive chemotherapy without bone marrow transplantation.
Neidhart J; Mangalik A; Kohler W; Stidley C; Saiki J; Duncan P; Souza L; Downing M
J Clin Oncol; 1989 Nov; 7(11):1685-92. PubMed ID: 2478670
[TBL] [Abstract][Full Text] [Related]
3. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.
Lemoli RM; Rosti G; Visani G; Gherlinzoni F; Miggiano MC; Fortuna A; Zinzani P; Tura S
J Clin Oncol; 1996 Nov; 14(11):3018-25. PubMed ID: 8918500
[TBL] [Abstract][Full Text] [Related]
4. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
5. GM-CSF accelerates neutrophil recovery after autologous bone marrow transplantation for Hodgkin's disease.
Devereaux S; Linch DC; Gribben JG; McMillan A; Patterson K; Goldstone AH
Bone Marrow Transplant; 1989 Jan; 4(1):49-54. PubMed ID: 2647187
[TBL] [Abstract][Full Text] [Related]
6. Use of recombinant human hematopoietic growth factors and autologous bone marrow transplantation to attenuate the neutropenic trough of high-dose therapy.
Spitzer G; Deisseroth A; Ventura G; Jagannath S; Fogel B; Taylor K; Huan S; Dunphy F; Dicke K; Souza L
Int J Cell Cloning; 1990 Jan; 8 Suppl 1():249-59; discussion 259-61. PubMed ID: 1691246
[TBL] [Abstract][Full Text] [Related]
7. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
8. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
Stahel RA; Jost LM; Cerny T; Pichert G; Honegger H; Tobler A; Jacky E; Fey M; Platzer E
J Clin Oncol; 1994 Sep; 12(9):1931-8. PubMed ID: 7521907
[TBL] [Abstract][Full Text] [Related]
9. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
[TBL] [Abstract][Full Text] [Related]
10. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation.
Brandt SJ; Peters WP; Atwater SK; Kurtzberg J; Borowitz MJ; Jones RB; Shpall EJ; Bast RC; Gilbert CJ; Oette DH
N Engl J Med; 1988 Apr; 318(14):869-76. PubMed ID: 3281007
[TBL] [Abstract][Full Text] [Related]
11. Delayed administration of granulocyte colony-stimulating factor after autologous bone marrow transplantation: effect on granulocyte recovery.
Vey N; Molnar S; Faucher C; Le Corroller AG; Stoppa AM; Viens P; Bouabdallah R; Camerlo J; Novakovitch G; Mannoni P
Bone Marrow Transplant; 1994 Nov; 14(5):779-82. PubMed ID: 7534161
[TBL] [Abstract][Full Text] [Related]
12. Post-5-fluorouracil human marrow: stem cell characteristics and renewal properties after autologous marrow transplantation.
Stewart FM; Temeles D; Lowry P; Thraves T; Grosh WW; Quesenberry PJ
Blood; 1993 May; 81(9):2283-9. PubMed ID: 8481510
[TBL] [Abstract][Full Text] [Related]
13. Role of granulocyte-macrophage colony stimulating factor (GM-CSF) after autologous bone marrow transplantation for Hodgkin's disease.
Gulati S; Bennett C; Toia M; Gopal A; Gopal R
Anticancer Drugs; 1993 May; 4 Suppl 1():13-6. PubMed ID: 8347851
[TBL] [Abstract][Full Text] [Related]
14. Clinical effects of recombinant human granulocyte colony-stimulating factor in leukemia patients: a phase I/II study.
Teshima H; Ishikawa J; Kitayama H; Yamagami T; Hiraoka A; Nakamura H; Shibata H; Masaoka T; Takaku F
Exp Hematol; 1989 Sep; 17(8):853-8. PubMed ID: 2475358
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
16. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF.
Hohaus S; Goldschmidt H; Ehrhardt R; Haas R
Exp Hematol; 1993 Apr; 21(4):508-14. PubMed ID: 7681782
[TBL] [Abstract][Full Text] [Related]
17. [Effect of recombinant human granulocyte colony stimulating factor (rhG-CSF) in patients receiving chemotherapy--phase I study].
Fukutani H; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nagamine D; Shinagawa K; Tabata M; Hirano A; Mizunuma N
Gan To Kagaku Ryoho; 1989 May; 16(5):2005-12. PubMed ID: 2471461
[TBL] [Abstract][Full Text] [Related]
18. Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in patients with acute myelogenous leukemia.
Demirer T; Buckner CD; Appelbaum FR; Petersen FB; Rowley S; Weaver CH; Lilleby K; Sanders J; Chauncey T; Storb R
Bone Marrow Transplant; 1995 Jun; 15(6):915-22. PubMed ID: 7581091
[TBL] [Abstract][Full Text] [Related]
19. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.
Schmitz N; Dreger P; Zander AR; Ehninger G; Wandt H; Fauser AA; Kolb HJ; Zumsprekel A; Martin A; Hecht T
Bone Marrow Transplant; 1995 Feb; 15(2):261-6. PubMed ID: 7539668
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
Wheeler C; Antin JH; Churchill WH; Come SE; Smith BR; Bubley GJ; Rosenthal DS; Rappaport JM; Ault KA; Schnipper LE
J Clin Oncol; 1990 Apr; 8(4):648-56. PubMed ID: 2313334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]